Edwards Lifesciences Co. (NYSE:EW) Shares Purchased by Worldquant Millennium Advisors LLC

Worldquant Millennium Advisors LLC increased its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 20.9% in the 4th quarter, Holdings Channel.com reports. The firm owned 726,004 shares of the medical research company’s stock after acquiring an additional 125,487 shares during the quarter. Worldquant Millennium Advisors LLC’s holdings in Edwards Lifesciences were worth $53,746,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Crowley Wealth Management Inc. purchased a new stake in shares of Edwards Lifesciences in the 4th quarter valued at approximately $26,000. Millstone Evans Group LLC acquired a new position in Edwards Lifesciences in the fourth quarter valued at approximately $29,000. Migdal Insurance & Financial Holdings Ltd. acquired a new position in Edwards Lifesciences in the fourth quarter valued at approximately $30,000. Catalyst Capital Advisors LLC acquired a new position in Edwards Lifesciences in the fourth quarter valued at approximately $54,000. Finally, SBI Securities Co. Ltd. acquired a new position in Edwards Lifesciences in the fourth quarter valued at approximately $62,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 11,250 shares of the company’s stock in a transaction on Friday, May 9th. The shares were sold at an average price of $74.40, for a total value of $837,000.00. Following the completion of the transaction, the chief financial officer now owns 41,098 shares in the company, valued at $3,057,691.20. This represents a 21.49% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP Donald E. Bobo, Jr. sold 9,500 shares of the company’s stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $67.96, for a total transaction of $645,620.00. Following the completion of the transaction, the vice president now owns 46,936 shares of the company’s stock, valued at $3,189,770.56. This represents a 16.83% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 66,192 shares of company stock worth $4,709,454. Corporate insiders own 1.29% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on EW. Truist Financial cut their target price on Edwards Lifesciences from $78.00 to $75.00 and set a “hold” rating on the stock in a research report on Friday, April 11th. Robert W. Baird boosted their target price on Edwards Lifesciences from $72.00 to $75.00 and gave the company a “neutral” rating in a research report on Thursday, April 24th. Morgan Stanley boosted their target price on Edwards Lifesciences from $70.00 to $75.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 12th. Canaccord Genuity Group boosted their target price on Edwards Lifesciences from $71.00 to $75.00 and gave the company a “hold” rating in a research report on Friday, April 25th. Finally, Evercore ISI cut their price objective on Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating on the stock in a research report on Wednesday, February 12th. One equities research analyst has rated the stock with a sell rating, thirteen have given a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat, Edwards Lifesciences currently has an average rating of “Hold” and a consensus target price of $79.60.

Edwards Lifesciences Stock Performance

Shares of EW stock opened at $78.02 on Tuesday. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The firm has a fifty day moving average price of $72.27 and a 200 day moving average price of $71.86. The company has a market cap of $45.77 billion, a P/E ratio of 11.19, a PEG ratio of 4.82 and a beta of 1.12. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $95.25.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Wednesday, April 23rd. The medical research company reported $0.64 EPS for the quarter, topping analysts’ consensus estimates of $0.60 by $0.04. The firm had revenue of $1.41 billion during the quarter, compared to the consensus estimate of $1.40 billion. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. The company’s revenue was up 6.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.66 earnings per share. Sell-side analysts predict that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.